Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Research save search
ACM Research to Release First Quarter 2024 Preliminary Revenue Range on April 26, 2024 and Full Financial Results on May 8, 2024
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
ACMR | $25.74 2.96% 2.87% 1M
|
Producer Manufacturing
| Email alert
Add to watchlist
first revenue research financial results
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $125.26 2.08% 0.18% 3.6M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
MDNAF | $1.19 -17.54% 72K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 ongoing expansion results study
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
IINN | $1.9 5.56% 5.26% 61K
|
Manufacturing
|
| O: 2.06%
H: 19.19%
C: 5.05%
bloodstream infections results show growth study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.19 -17.54% 72K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.19 -17.54% 72K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
ALKS | $24.06 0.88% 0.87% 1.7M
|
Health Technology
|
| O: 4.48%
H: 0.82%
C: -2.05%
narcolepsy positive topline results study
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.43 -0.31% -0.31% 550K
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
CYDX | $0.41 -14.15% 290
|
n/a
| Email alert
Add to watchlist
breast biomarker positive cancer diagnostics results study
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
PTPI | $0.677 1.03% 1.02% 200K
|
| Email alert
Add to watchlist
positive pharmaceuticals results study
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.79 0.63% 0.63% 140K
|
Health Technology
|
| O: -2.27%
H: 0.0%
C: 0.0%
positive treatment results study
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Published: 2024-03-20 (Crawled : 12:30) - globenewswire.com
RSPI | $0.0009 0.0% 1.2M
|
Manufacturing
|
| O: 0.0%
H: 25.0%
C: 25.0%
cx1739 bladder publication pharmaceuticals research preclinical results
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
VSTM | $9.695 -1.47% -1.5% 95K
|
Health Technology
|
| O: 0.0%
H: 1.18%
C: -3.45%
reveal cancer global impact results living negative
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
Published: 2024-03-15 (Crawled : 10:00) - prnewswire.com
SOPH | $4.99 0.61% 0.6% 170K
|
|
| O: 3.8%
H: 7.84%
C: 2.06%
kidney cancer research collaboration network results
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
EXAS | $62.41 2.38% 2.32% 1.6M
|
Health Technology
|
| O: -0.43%
H: 1.9%
C: 1.06%
cologuard test results study
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
Published: 2024-03-12 (Crawled : 11:00) - biospace.com/
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 2.17%
H: 2.12%
C: -0.71%
mn-166 lung meeting results
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ERNA | $2.15 0.46% 5.6K
|
Information
|
| O: 1.17%
H: 10.27%
C: 10.27%
LCTX | $1.14 -0.87% 0.0% 420K
|
Health Technology
|
| O: -5.38%
H: 17.89%
C: 4.88%
rg6501 opregen association research preclinical vision meeting results
Research Frontiers Reports Fourth Quarter and Year-End 2023 Financial Results and Will Host a Conference Call at 4:30p.m. Today
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
REFR | $1.53 0.0% 25K
|
Electronic Technology
|
| O: 12.39%
H: 11.81%
C: 3.94%
conference research financial results today
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.